中国医疗设备
中國醫療設備
중국의료설비
CHINA MEDICAL EQUIPMENT
2014年
10期
153-155
,共3页
脑转移瘤%全脑放射治疗%立体定向放疗%三维适形放疗
腦轉移瘤%全腦放射治療%立體定嚮放療%三維適形放療
뇌전이류%전뇌방사치료%입체정향방료%삼유괄형방료
brain metastasis%whole brain radiotherapy%stereotactic radiotherapy%three dimensional conformal radiation therapy
目的：分析和总结三维适形放疗与立体定向放疗在治疗脑转移瘤中的疗效。方法回顾性分析2009年11月~2011年11月于我院行全脑放疗后行三维适形放疗或立体定向放疗的60例肺癌脑转移患者的放疗资料、随访资料及影像学资料，比较两种放疗方式的疗效。结果本组含1～2个脑转移灶的患者共21例，12例行三维适形放疗，9例行立体定向放疗，两组患者的中位生存期、有效率和1年生存率分别为12月、83.3%、58.3%和14月、88.9%、66.7%。脑转移灶数≥3的患者共39例，17例行三维适形放疗，22例行立体定向放疗，两组的中位生存期、有效率和1年生存率分别为7月、58.8%、41.2%和13月、81.8%、68.2%。在脑转移灶数≥3的患者中，立体定向放疗组的中位生存期、有效率和1年生存率都明显优于三维适形放疗组（P＜0.05）。结论对于多发性脑转移瘤患者，立体定向放疗较三维适形放疗更有效。
目的：分析和總結三維適形放療與立體定嚮放療在治療腦轉移瘤中的療效。方法迴顧性分析2009年11月~2011年11月于我院行全腦放療後行三維適形放療或立體定嚮放療的60例肺癌腦轉移患者的放療資料、隨訪資料及影像學資料，比較兩種放療方式的療效。結果本組含1～2箇腦轉移竈的患者共21例，12例行三維適形放療，9例行立體定嚮放療，兩組患者的中位生存期、有效率和1年生存率分彆為12月、83.3%、58.3%和14月、88.9%、66.7%。腦轉移竈數≥3的患者共39例，17例行三維適形放療，22例行立體定嚮放療，兩組的中位生存期、有效率和1年生存率分彆為7月、58.8%、41.2%和13月、81.8%、68.2%。在腦轉移竈數≥3的患者中，立體定嚮放療組的中位生存期、有效率和1年生存率都明顯優于三維適形放療組（P＜0.05）。結論對于多髮性腦轉移瘤患者，立體定嚮放療較三維適形放療更有效。
목적：분석화총결삼유괄형방료여입체정향방료재치료뇌전이류중적료효。방법회고성분석2009년11월~2011년11월우아원행전뇌방료후행삼유괄형방료혹입체정향방료적60례폐암뇌전이환자적방료자료、수방자료급영상학자료，비교량충방료방식적료효。결과본조함1～2개뇌전이조적환자공21례，12례행삼유괄형방료，9례행입체정향방료，량조환자적중위생존기、유효솔화1년생존솔분별위12월、83.3%、58.3%화14월、88.9%、66.7%。뇌전이조수≥3적환자공39례，17례행삼유괄형방료，22례행입체정향방료，량조적중위생존기、유효솔화1년생존솔분별위7월、58.8%、41.2%화13월、81.8%、68.2%。재뇌전이조수≥3적환자중，입체정향방료조적중위생존기、유효솔화1년생존솔도명현우우삼유괄형방료조（P＜0.05）。결론대우다발성뇌전이류환자，입체정향방료교삼유괄형방료경유효。
Objective To analyze and conclude the efficacy of three dimensional conformal radiation therapy (3D-CRT) and stereotactic radiation therapy (SRT) in the treatment of brain metastasis. Methods Data of 60 patients who suffered from lung cancer with brain metastasis were retrospectively analyzed. From November 2009 to November 2011, these patients were all treated in our hospital either by SRT or 3D-CRT after whole brain radiotherapy. The radiotherapy data, follow-up data and imaging data of the patients were analyzed to compare the efifcacy of the two therapies. Results Among 21 patients with one or two brain metastases, 12 patients went through 3D-CRT and 9 went through SRT. The median survival time, effective rate and one year survival rate of these two groups are 12 months, 83.3%, 58.3%and 14 months, 88.9%, 66.7%, respectively. Among 39 patients with more than three brain metastases, 17 patients went through 3D-CRT and 22 went through SRT. The median survival time, effective rate and one year survival rate of the two groups are 7 months,58.8%,41.2%and 13 months,81.8%,68.2%, respectively. So to patients with more than three brain metastases, median survival time, effective rate and one year survival rate of SRT group were signiifcantly better than those of 3D-CRT group (P<0.05). Conclusion For patients with multiple brain metastases, SRT was more effective than 3D-CRT.
